Intranasal Administration of Hsp70: Molecular and Therapeutic Consequences

  • Michael B. Evgen’ev
  • David G. Garbuz
  • Alexei V. Morozov
  • Natalia V. Bobkova
Part of the Heat Shock Proteins book series (HESP, volume 14)


Hsp70 and other molecular chaperones function as a complex neuroprotective system, which fails in the brains of aged people and Alzheimer’s disease (AD)-type neuropathologies. It was demonstrated that intranasally injected exogenous Hsp70 (eHsp70) effectively bypassed the blood-brain barrier and penetrates brain regions of the model animals. It was shown that chronic administration of eHsp70 decreases beta-amyloid level and the number of Aβ-plaques in two mouse models of AD. In both cases eHsp70 restored learning and memory parameters as well as functional state of neurons. Characteristically, eHsp70 treatment increased synaptophysin level and protects neurons in brain areas most affected in AD patients such as hippocampus and neocortex. It was also demonstrated that eHsp70 can promote longevity and life quality in male mice. The eHsp70 treatment decreased accumulation of aging marker lipofuscin and modulates the activity of UPS by increasing expression of several proteasome subunits including immunoproteasome subunit β5i. Deep sequencing studies exploring brain regions of AD-model – 5XFAD mice treated with eHsp70 revealed candidate genes and signal pathways probably underlying beneficial effects of eHsp70 treatment. Taken together, our findings establish intranasal administration of exogenous human Hsp70 as a practical therapeutic approach for the treatment of various neurodegenerative diseases and aging.


Aging Deep sequencing Hsp70 Intranasal administration Mouse model of AD 



Alzheimer’s disease


Amyloid precursor protein


Bcl-2-associated athanogene-1


Blood-brain barrier


Bovine serum albumin


Carboxy-terminus of Hsc70-interacting protein


Central nervous system


Heat shock protein




Lipoteichoic acid


N-methyl-D-aspartate receptor




Reactive oxygen species


Toll-like receptor


Tumor necrosis factor


Ubiquitin-proteasome system



The work was supported by Russian Science Foundation Grant №14-50-00060 and Program of fundamental research for state academies for 2013-2020 years (N-01201363817).


  1. Abkin, S. V., Pankratova, K. M., Komarova, E. Y., Guzhova, I. V., & Margulis, B. A. (2013). Hsp70 chaperone-based gel composition as a novel immunotherapeutic anti-tumor tool. Cell Stress & Chaperones, 18(3), 391–396.CrossRefGoogle Scholar
  2. Abkin, S. V., Ostroumova, O. S., Komarova, E. Y., et al. (2016). Phloretin increases the anti-tumor efficacy of intratumorally delivered heat-shock protein 70 kDa (HSP70) in a murine model of melanoma. Cancer Immunology, Immunotherapy, 65(1), 83–92.CrossRefPubMedGoogle Scholar
  3. Agulla, J., Brea, D., Argibay, B., et al. (2014). Quick adjustment of imaging tracer payload, for in vivo applications of theranostic nanostructures in the brain. Nanomedicine, 10(4), 851–858.CrossRefPubMedGoogle Scholar
  4. Asea, A., & Brown, J. (Eds.). (2008). Heat shock proteins and the brain: Implications for neurodegenerative diseases and neuroprotection. Dordrecht: Springer.Google Scholar
  5. Asea, A., Rehli, M., Kabingu, E., et al. (2002). Novel signal transduction pathway utilized by extracellular HSP70: Role of toll-like receptor (TLR) 2 and TLR4. The Journal of Biological Chemistry, 277(17), 15028–15034.CrossRefPubMedGoogle Scholar
  6. Bence, N. F., Sampat, R. M., & Kopito, R. R. (2001). Impairment of the ubiquitin-proteasome system by protein aggregation. Science, 292(5521), 1552–1555.CrossRefPubMedGoogle Scholar
  7. Bertoni-Freddari, C., Fattoretti, P., Casoli, T., Caselli, U., & Meier-Ruge, W. (1996). Deterioration threshold of synaptic morphology in aging and senile dementia of Alzheimer’s type. Analytical and Quantitative Cytology and Histology, 18(3), 209–213.PubMedGoogle Scholar
  8. Bobkova, N. V., Nesterova, I. V., Medvinskaya, N. I., et al. (2005). Possible role of the olfactory system in Alzheimer’s disease genesis. In A. Fisher, I. Hanin, M. Memo, & F. Stocchi (Eds.), New trends in Alzheimer and Parkinson disorders: ADPD 2005 (pp. 91–95). Sorento: Medimond.Google Scholar
  9. Bobkova, N., Vorobyov, V., Medvinskaya, N., Aleksandrova, I., & Nesterova, I. (2008). Interhemispheric EEG differences in olfactory bulbectomized rats with different cognitive abilities and brain beta-amyloid levels. Brain Research, 1232, 185–194.CrossRefPubMedGoogle Scholar
  10. Bobkova, N., Guzhova, I., Margulis, B., et al. (2013). Dynamics of endogenous Hsp70 synthesis in the brain of olfactory bulbectomized mice. Cell Stress & Chaperones, 18(1), 109–118.CrossRefGoogle Scholar
  11. Bobkova, N. V., Garbuz, D. G., Nesterova, I., et al. (2014). Therapeutic effect of exogenous hsp70 in mouse models of Alzheimer’s disease. Journal of Alzheimer’s Disease, 38(2), 425–435.CrossRefPubMedGoogle Scholar
  12. Bobkova, N. V., Evgen’ev, M., Garbuz, D. G., et al. (2015). Exogenous Hsp70 delays senescence and improves cognitive function in aging mice. Proceedings of the National Academy of Sciences of the United States of America, 112(52), 16006–16011.CrossRefPubMedPubMedCentralGoogle Scholar
  13. Calderwood, S. K., & Murshid, A. (2017). Molecular chaperone accumulation in cancer and decrease in Alzheimer’s disease: The potential roles of HSF1. Frontiers in Neuroscience, 11, 192.CrossRefPubMedPubMedCentralGoogle Scholar
  14. Calderwood, S. K., Gong, J., & Murshid, A. (2016). Extracellular HSPs: The complicated roles of extracellular HSPs in immunity. Frontiers in Immunology, 7, 159.PubMedPubMedCentralGoogle Scholar
  15. Choi, J., Malakowsky, C. A., Talent, J. M., Conrad, C. C., & Gracy, R. W. (2002). Identification of oxidized plasma proteins in Alzheimer’s disease. Biochemical and Biophysical Research Communications, 293(5), 1566–1570.CrossRefPubMedGoogle Scholar
  16. Chondrogianni, N., & Gonos, E. S. (2010). Proteasome function determines cellular homeostasis and the rate of aging. Advances in Experimental Medicine and Biology, 694, 38–46.CrossRefPubMedGoogle Scholar
  17. Chondrogianni, N., Petropoulos, I., Franceschi, C., Friguet, B., & Gonos, E. S. (2000). Fibroblast cultures from healthy centenarians have an active proteasome. Experimental Gerontology, 35(6–7), 721–728.CrossRefPubMedGoogle Scholar
  18. Chondrogianni, N., Voutetakis, K., Kapetanou, M., et al. (2015). Proteasome activation: An innovative promising approach for delaying aging and retarding age-related diseases. Ageing Research Reviews, 23(Pt A), 37–55.CrossRefPubMedGoogle Scholar
  19. Cudkowicz, M. E., Shefner, J. M., Simpson, E., et al. (2008). Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis. Muscle & Nerve, 38(1), 837–844.CrossRefGoogle Scholar
  20. Duncan, E. J., Cheetham, M. E., Chapple, J. P., & van der Spuy, J. (2015). The role of HSP70 and its co-chaperones in protein misfolding, aggregation and disease. Sub-Cellular Biochemistry, 78, 243–273.CrossRefPubMedGoogle Scholar
  21. Ekimova, I. V., Nitsinskaya, L. E., Romanova, I. V., Pastukhov, Y. F., Margulis, B. A., & Guzhova, I. V. (2010). Exogenous protein Hsp70/Hsc70 can penetrate into brain structures and attenuate the severity of chemically-induced seizures. Journal of Neurochemistry, 115(4), 1035–1044.CrossRefPubMedGoogle Scholar
  22. Evgen’Ev, M. B., Garbuz, D. G., & Zatsepina, O. G. (2014). Heat shock proteins and whole body adaptation to extreme environments (Vol. XVII, p. 218). Dordrecht: Springer.Google Scholar
  23. Falcone, J. A., Salameh, T. S., Yi, X., et al. (2014). Intranasal administration as a route for drug delivery to the brain: Evidence for a unique pathway for albumin. The Journal of Pharmacology and Experimental Therapeutics, 351(1), 54–60.CrossRefPubMedPubMedCentralGoogle Scholar
  24. Ferrington, D. A., & Gregerson, D. S. (2012). Immunoproteasomes: Structure, function, and antigen presentation. In T. Grune (Ed.), The proteasomal system in aging and disease (Progress in molecular biology and translational science, Vol. 109, pp. 75–112). Amsterdam: Academic.Google Scholar
  25. Ferrington, D. A., Husom, A. D., & Thompson, L. V. (2005). Altered proteasome structure, function, and oxidation in aged muscle. The FASEB Journal, 19(6), 644–646.CrossRefPubMedGoogle Scholar
  26. Fleshner, M., & Johnson, J. D. (2005). Endogenous extra-cellular heat shock protein 72: Releasing signal(s) and function. International Journal of Hyperthermia, 21(5), 457–471.CrossRefPubMedGoogle Scholar
  27. Franklin, T. B., Krueger-Naug, A. M., Clarke, D. B., Arrigo, A. P., & Currie, R. W. (2005). The role of heat shock proteins Hsp70 and Hsp27 in cellular protection of the central nervous system. International Journal of Hyperthermia, 21(5), 379–392.CrossRefPubMedGoogle Scholar
  28. Gehrig, S. M., van der Poel, C., Sayer, T. A., et al. (2012). Hsp72 preserves muscle function and slows progression of severe muscular dystrophy. Nature, 484(7394), 394–398.CrossRefPubMedGoogle Scholar
  29. Gendelman, H. E., Anantharam, V., Bronich, T., et al. (2015). Nanoneuromedicines for degenerative, inflammatory, and infectious nervous system diseases. Nanomedicine, 11(3), 751–767.CrossRefPubMedPubMedCentralGoogle Scholar
  30. Gifondorwa, D. J., Robinson, M. B., Hayes, C. D., et al. (2008). Exogenous delivery of heat shock protein 70 increases lifespan in a mouse model of amyotrophic lateral sclerosis. The Journal of Neuroscience, 27(48), 13173–13180.CrossRefGoogle Scholar
  31. Glickman, M. H., & Ciechanover, A. (2002). The ubiquitin-proteasome proteolytic pathway: Destruction for the sake of construction. Physiological Reviews, 82(2), 373–428.CrossRefPubMedGoogle Scholar
  32. Gong, J., Zhu, B., Murshid, A., et al. (2009). T cell activation by heat shock protein 70 vaccine requires TLR signaling and scavenger receptor expressed by endothelial cells-1. Journal of Immunology, 183(5), 3092–3098.CrossRefGoogle Scholar
  33. Grune, T., Catalgol, B., Licht, A., et al. (2011). HSP70 mediates dissociation and reassociation of the 26S proteasome during adaptation to oxidative stress. Free Radical Biology & Medicine, 51(7), 1355–1364.CrossRefGoogle Scholar
  34. Gurskiy, Y. G., Garbuz, D. G., Soshnikova, N. V., et al. (2016). The development of modified human Hsp70 (HSPA1A) and its production in the milk of transgenic mice. Cell Stress & Chaperones, 21(6), 1055–1064.CrossRefGoogle Scholar
  35. Guzhova, I., Kislyakova, K., Moskaliova, O., et al. (2001). In vitro studies show that Hsp70 can be released by glia and that exogenous Hsp70 can enhance neuronal stress tolerance. Brain Research, 914(1–2), 66–73.CrossRefPubMedGoogle Scholar
  36. Guzhova, I., & Margulis, B. (2006). Hsp70 chaperone as a survival factor in cell pathology. International Review of Cytology, 254, 101–149.CrossRefPubMedGoogle Scholar
  37. Hanson, L. R., & Frey, W. H., 2nd. (2008). Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neuroscience, 9(Suppl. 3), S5.CrossRefPubMedPubMedCentralGoogle Scholar
  38. Hipkiss, A. R. (2006). Accumulation of altered proteins and ageing: Causes and effects. Experimental Gerontology, 41(5), 464–473.CrossRefPubMedGoogle Scholar
  39. Hoshino, T., Murao, N., Namba, T., et al. (2011). Suppression of Alzheimer’s disease-related phenotypes by expression of heat shock protein 70 in mice. The Journal of Neuroscience, 31(14), 5225–5234.CrossRefPubMedGoogle Scholar
  40. Hoshino, T., Suzuki, K., Matsushima, T., Yamakawa, N., Suzuki, T., & Mizushima, T. (2013). Suppression of Alzheimer’s disease-related phenotypes by geranylgeranylacetone in mice. PLoS One, 8(10), e76306.CrossRefPubMedPubMedCentralGoogle Scholar
  41. Jinwal, U. K., Koren, J., O’Leary, J. C., Jones, J. R., Abisambra, J. F., & Dickey, C. A. (2010). Hsp70 ATPase modulators as therapeutics for Alzheimer’s and other neurodegenerative diseases. Molecular and Cellular Pharmacology, 2(2), 43–46.PubMedPubMedCentralGoogle Scholar
  42. Johnson, J. D., & Fleshner, M. (2006). Releasing signals, secretory pathways, and immune function of endogenous extracellular heat shock protein 72. Journal of Leukocyte Biology, 79(3), 425–434.CrossRefPubMedGoogle Scholar
  43. Kästle, M., & Grune, T. (2012). Interactions of the proteasomal system with chaperones: Protein triage and protein quality control. In T. Grune (Ed.), The proteasomal system in aging and disease (Progress in molecular biology and translational science, Vol. 109, pp. 113–160). Amsterdam: Academic.Google Scholar
  44. Keller, J. N., Huang, F. F., & Markesbery, W. R. (2000). Decreased levels of proteasome activity and proteasome expression in aging spinal cord. Neuroscience, 98(1), 149–156.CrossRefPubMedGoogle Scholar
  45. Kirkegaard, T., Gray, J., Priestman, D. A., et al. (2016). Heat shock protein-based therapy as a potential candidate for treating the sphingolipidoses. Science Translational Medicine, 8(355), 355ra118.CrossRefPubMedGoogle Scholar
  46. Kustanova, G. A., Murashev, A. N., Karpov, V. L., et al. (2006). Exogenous heat shock protein 70 mediates sepsis manifestations and decreases the mortality rate in rats. Cell Stress & Chaperones, 11(3), 276–286.CrossRefGoogle Scholar
  47. Li, Y., Wang, Y. S., Shen, X. F., et al. (2008). Alterations of activity and intracellular distribution of the 20S proteasome in ageing retinal pigment epithelial cells. Experimental Gerontology, 43(12), 1114–1122.CrossRefPubMedGoogle Scholar
  48. Margulis, B., Kinev, A., & Guzhova, I. (2006). Chaperones in neurodegenerative pathologies: Therapeutic prospects. In J. Radons & G. Multhoff (Eds.), Heat shock proteins in biology and medicine (pp. 305–329). Trivandrum: Research Singpost.Google Scholar
  49. Morimoto, R. I. (2011). The heat shock response: Systems biology of proteotoxic stress in aging and disease. Cold Spring Harbor Symposia on Quantitative Biology, 76, 91–99.CrossRefPubMedGoogle Scholar
  50. Morimoto, R. I., & Cuervo, A. M. (2014). Proteostasis and the aging proteome in health and disease. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences, 69(Suppl 1), S33–S38.CrossRefPubMedPubMedCentralGoogle Scholar
  51. Morozov, A. V., Astakhova, T. M., Garbuz, D. G., et al. (2017). Interplay between recombinant Hsp70 and proteasomes: Proteasome activity modulation and ubiquitin-independent cleavage of Hsp70. Cell Stress & Chaperones.
  52. Morrissette, D. A., Parachikova, A., Green, K. N., & LaFerla, F. M. (2009). Relevance of transgenic mouse models to human Alzheimer disease. The Journal of Biological Chemistry, 284(10), 6033–6037.CrossRefPubMedGoogle Scholar
  53. Multhoff, G., & Hightower, L. E. (2011). Distinguishing integral and receptor-bound heat shock protein 70 (Hsp70) on the cell surface by Hsp70-specific antibodies. Cell Stress & Chaperones, 16(3), 251–255.CrossRefGoogle Scholar
  54. Murshid, A., Eguchi, T., & Calderwood, S. K. (2013). Stress proteins in aging and life span. International Journal of Hyperthermia, 29(5), 442–447.CrossRefPubMedPubMedCentralGoogle Scholar
  55. Oakley, H., Cole, S. L., Logan, S., et al. (2006). Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer’s disease mutations: Potential factors in amyloid plaque formation. The Journal of Neuroscience, 26(40), 10129–10140.CrossRefPubMedGoogle Scholar
  56. Pickering, A. M., Koop, A. L., Teoh, C. Y., Ermak, G., Grune, T., & Davies, K. J. (2010). The immunoproteasome, the 20S proteasome and the PA28αβ proteasome regulator are oxidative-stress-adaptive proteolytic complexes. The Biochemical Journal, 432(3), 585–594.CrossRefPubMedPubMedCentralGoogle Scholar
  57. Pickering, A. M., Lehr, M., & Miller, R. A. (2015). Lifespan of mice and primates correlates with immunoproteasome expression. The Journal of Clinical Investigation, 125(5), 2059–2068.CrossRefPubMedPubMedCentralGoogle Scholar
  58. Pratt, W. B., Gestwicki, J. E., Osawa, Y., & Lieberman, A. P. (2015). Targeting Hsp90/Hsp70-based protein quality control for treatment of adult onset neurodegenerative diseases. Annual Review of Pharmacology and Toxicology, 55, 353–371.CrossRefPubMedGoogle Scholar
  59. Radons, J. (2016). The human HSP70 family of chaperones: Where do we stand? Cell Stress & Chaperones, 21(3), 379–404.CrossRefGoogle Scholar
  60. Rattan, S. I. (1996). Synthesis, modifications, and turnover of proteins during aging. Experimental Gerontology, 31(1–2), 33–47.CrossRefPubMedGoogle Scholar
  61. Reeg, S., Jung, T., Castro, J. P., Davies, K. J. A., Henze, A., & Grune, T. (2016). The molecular chaperone Hsp70 promotes the proteolytic removal of oxidatively damaged proteins by the proteasome. Free Radical Biology & Medicine, 99, 153–166.CrossRefGoogle Scholar
  62. Rodriguez, K. A., Edrey, Y. H., Osmulski, P., Gaczynska, M., & Buffenstein, R. (2012). Altered composition of liver proteasome assemblies contributes to enhanced proteasome activity in the exceptionally long-lived naked mole-rat. PLoS One, 7(5), e35890.CrossRefPubMedPubMedCentralGoogle Scholar
  63. Seifert, U., Bialy, L. P., Ebstein, F., et al. (2010). Immunoproteasomes preserve protein homeostasis upon interferon-induced oxidative stress. Cell, 142, 613–624.CrossRefPubMedGoogle Scholar
  64. Shevtsov, M. A., Nikolaev, B. P., Yakovleva, L. Y., Parr, M. A., Marchenko, Y. Y., Eliseev, I., Yudenko, A., Dobrodumov, A. V., Zlobina, O., Zhakhov, A., Ischenko, A. M., Pitkin, E., & Multhoff, G. (2015). 70-kDa heat shock protein coated magnetic nanocarriers as a nanovaccine for induction of anti-tumor immune response in experimental glioma. Journal of Controlled Release, 220(Pt A), 329–340.CrossRefPubMedGoogle Scholar
  65. Shevtsov, M. A., Nikolaev, B. P., Ryzhov, V. A., et al. (2016). Detection of experimental myocardium infarction in rats by MRI using heat shock protein 70 conjugated superparamagnetic iron oxide nanoparticle. Nanomedicine, 12(3), 611–621.CrossRefPubMedGoogle Scholar
  66. Sitte, N., Huber, M., Grune, T., et al. (2000). Proteasome inhibition by lipofuscin/ceroid during postmitotic aging of fibroblasts. The FASEB Journal, 14(11), 1490–1498.CrossRefPubMedGoogle Scholar
  67. Soti, C., & Csermely, P. (2002). Chaperones come of age. Cell Stress & Chaperones, 7(2), 186–190.CrossRefGoogle Scholar
  68. Tönnies, E., & Trushina, E. (2017). Oxidative stress, synaptic dysfunction, and Alzheimer’s disease. Journal of Alzheimer’s Disease, 57(4), 1105–1121.CrossRefPubMedPubMedCentralGoogle Scholar
  69. Vinokurov, M., Ostrov, V., Yurinskaya, M., et al. (2012). Recombinant human Hsp70 protects against lipoteichoic acid-induced inflammation manifestations at the cellular and organismal levels. Cell Stress & Chaperones, 17(1), 89–101.CrossRefGoogle Scholar
  70. Viteri, G., Carrard, G., Birlouez-Aragón, I., Silva, E., & Friguet, B. (2004). Age-dependent protein modifications and declining proteasome activity in the human lens. Archives of Biochemistry and Biophysics, 427(2), 197–203.CrossRefPubMedGoogle Scholar
  71. Wright, K. L., White, L. C., Kelly, A., Beck, S., Trowsdale, J., & Ting, J. P. (1995). Coordinate regulation of the human TAP1 and LMP2 genes from a shared bidirectional promoter. The Journal of Experimental Medicine, 181(4), 1459–1471.CrossRefPubMedGoogle Scholar
  72. Ying, W. (2008). The nose may help the brain: Intranasal drug delivery for treating neurological diseases. Future Neurology, 3(1), 1–4.CrossRefGoogle Scholar
  73. Yurinskaya, M., Zatsepina, O. G., Vinokurov, M. G., et al. (2015). The fate of exogenous human HSP70 introduced into animal cells by different means. Current Drug Delivery, 12(5), 524–532.CrossRefPubMedGoogle Scholar
  74. Yurinskaya, M. M., Funikov, S. Y., Evgen’ev, M. B., & Vinokurov, M. G. (2016). Exogenous heat shock protein HSP70 reduces response of human neuroblastoma cells to lipopolysaccharide. Doklady Biochemistry and Biophysics, 469(1), 239–243.CrossRefPubMedGoogle Scholar
  75. Yurinskaya, M. M., Kochetkova, O. Y., Shabarchina, et al. (2017). Encapsulated Hsp70 decreases endotoxin-induced production of ROS and TNFα in human phagocytes. Cell Stress & Chaperones, 22(2), 163–171.CrossRefGoogle Scholar
  76. Zhang, C., Rodriguez, C., Spaulding, J., AW, T. Y., & Feng, J. (2012). Age-dependent and tissue-related glutathione redox status in a mouse model of Alzheimer’s disease. Journal of Alzheimer’s Disease, 28(3), 655–666.CrossRefPubMedGoogle Scholar
  77. Zheng, H., Nagaraja, G. M., Kaur, P., Asea, E. E., & Asea, A. (2010). Chaperokine function of recombinant Hsp72 produced in insect cells using a baculovirus expression system is retained. The Journal of Biological Chemistry, 285(1), 349–356.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Michael B. Evgen’ev
    • 1
    • 2
  • David G. Garbuz
    • 1
  • Alexei V. Morozov
    • 1
  • Natalia V. Bobkova
    • 2
  1. 1.Engelhardt Institute of Molecular BiologyMoscowRussia
  2. 2.Institute of Cell Biophysics, RASMoscowRussia

Personalised recommendations